Shruti H Mehta1, Aylur K Srikrishnan2, Eva Noble3, Canjeevaram K Vasudevan2, Suniti Solomon2, M Suresh Kumar2, Sunil S Solomon4. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. Electronic address: shmehta@jhsph.edu. 2. YR Gaitonde Centre for AIDS Research and Education, Chennai, India. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Abstract
BACKGROUND: Little is known regarding the epidemiology of drug injection and risk behaviors among injection drug users (IDUs) across India. In particular, there is limited data on the prevalence of stimulant injection. METHODS: We sampled 801 HIV positive IDUs from 14 locations throughout India to represent the geography of India as well as the diversity in IDU epidemic stage (established epidemics, emerging epidemics and large cities). All participants underwent a behavioral survey and blood draw. Given prior associations with stimulant injection and HIV risk, we compared stimulant injectors (cocaine and/or methamphetamine) to those who injected opiates and/or pharmaceuticals only. RESULTS: The median age was 33; 86% were male. The primary drugs injected were heroin, buprenorphine and other pharmaceuticals. In all but four sites, >50% of those actively injecting reported needle sharing. Stimulant injection was most common in emerging epidemics. Compared to exclusive opiate injectors, stimulant injectors were significantly younger, more likely to be educated and employed, more likely to report non-injection use of heroin, crack/cocaine and amphetamines, heavy alcohol use, recent needle sharing (71% vs. 57%), sex with a casual partner (57% vs. 31%) and men having sex with other men (33% vs. 9%; p<0.01 for all). CONCLUSIONS: Emerging IDU epidemics have a drug/sexual risk profile not previously been observed in India. Given the high prevalence of stimulant injection in these populations, HIV prevention/treatment programs may need to be redesigned to maximize effectiveness. The high levels of injection sharing overall reinforce the need to ensure access to harm-reduction services for all.
BACKGROUND: Little is known regarding the epidemiology of drug injection and risk behaviors among injection drug users (IDUs) across India. In particular, there is limited data on the prevalence of stimulant injection. METHODS: We sampled 801 HIV positive IDUs from 14 locations throughout India to represent the geography of India as well as the diversity in IDU epidemic stage (established epidemics, emerging epidemics and large cities). All participants underwent a behavioral survey and blood draw. Given prior associations with stimulant injection and HIV risk, we compared stimulant injectors (cocaine and/or methamphetamine) to those who injected opiates and/or pharmaceuticals only. RESULTS: The median age was 33; 86% were male. The primary drugs injected were heroin, buprenorphine and other pharmaceuticals. In all but four sites, >50% of those actively injecting reported needle sharing. Stimulant injection was most common in emerging epidemics. Compared to exclusive opiate injectors, stimulant injectors were significantly younger, more likely to be educated and employed, more likely to report non-injection use of heroin, crack/cocaine and amphetamines, heavy alcohol use, recent needle sharing (71% vs. 57%), sex with a casual partner (57% vs. 31%) and men having sex with other men (33% vs. 9%; p<0.01 for all). CONCLUSIONS: Emerging IDU epidemics have a drug/sexual risk profile not previously been observed in India. Given the high prevalence of stimulant injection in these populations, HIV prevention/treatment programs may need to be redesigned to maximize effectiveness. The high levels of injection sharing overall reinforce the need to ensure access to harm-reduction services for all.
Authors: Peter Freeman; Bendu C Walker; D Robert Harris; Robert Garofalo; Nancy Willard; Jonathan M Ellen Journal: Arch Pediatr Adolesc Med Date: 2011-08
Authors: Sunil S Solomon; Monica Desai; A K Srikrishnan; Easter Thamburaj; C K Vasudevan; M Suresh Kumar; Suniti Solomon; David D Celentano; Shruti H Mehta Journal: Subst Use Misuse Date: 2010-02 Impact factor: 2.164
Authors: Louisa Degenhardt; Bradley Mathers; Mauro Guarinieri; Samiran Panda; Benjamin Phillips; Steffanie A Strathdee; Mark Tyndall; Lucas Wiessing; Alex Wodak; John Howard Journal: Int J Drug Policy Date: 2010-02-01
Authors: Lakshmi Ganapathi; Allison M McFall; Aylur K Srikrishnan; Muniratnam S Kumar; Santhanam Anand; Gregory M Lucas; Shruti H Mehta; Sion K Harris; Sunil S Solomon Journal: J Int AIDS Soc Date: 2019-05 Impact factor: 5.396
Authors: Eshan U Patel; Sunil S Solomon; Gregory M Lucas; Allison M McFall; Cecília Tomori; Aylur K Srikrishnan; Muniratnam S Kumar; Oliver Laeyendecker; David D Celentano; David L Thomas; Thomas C Quinn; Shruti H Mehta Journal: Int J Drug Policy Date: 2021-07-08
Authors: Lei Zhang; Feng Cheng; Shu Su; Shunxiang Li; Shifu Li; Jun Jing; Christopher Kincaid Fairley; Liang Chen; Jinxian Zhao; Limin Mao Journal: BMJ Open Date: 2018-06-30 Impact factor: 2.692